The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at a concentration of 2 µg/ml. In the ELISA capture assay, plates are coated with 100 µl/well of the capture antibody (2 µg/ml) in combination with 100 µl/well of a detection antibody (affinity-purified biotinylated polyclonal anti-human IGFBP1 antibody at 100 ng/ml). An ELISA range of 62.4 to 4000 pg/ml may be obtained.
Neut: Use at a concentration of 10 - 40 µg/ml. The Neutralization Dose50 (ND50) for this antibody is 10-40 µg/ml in the presence of approximately 5 µg/ml of recombinant human IGFBP1 and approximately 6 ng/mL of recombinant human IGF1, using human MCF7 cells.
WB: Use at a concentration of 1 - 2 µg/ml. Predicted molecular weight: 28 kDa. The detection limit for recombinant human IGFBP1 is approximately 0.5 ng/lane under non-reducing conditions.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionIGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Promotes cell migration.
Growth hormone independent binding protein antibody
hIGFBP 1 antibody
IBP 1 antibody
IGF binding protein 1 antibody
IGF BP25 antibody
IGF-binding protein 1 antibody
IGFBP 1 antibody
Insulin like growth factor binding protein 1 antibody
Insulin-like growth factor-binding protein 1 antibody
Placental protein 12 antibody
PP 12 antibody
References for Anti-IGFBP1 antibody [33627.11] (ab10732)
This product has been referenced in:
Walker G et al. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res13:1438-44 (2007).
Read more (PubMed: 17332286) »